Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Memantine in an Extemporaneously Prepared Oral Liquid

Author(s):  Yamreudeewong Weeranuj, Teixeira M Glaucia, Mayer Gabriele E

Issue:  Jul/Aug 2006 - Sterile Preparations
View All Articles in Issue

Page(s):  316-317

Stability of Memantine in an Extemporaneously Prepared Oral Liquid Page 1
Stability of Memantine in an Extemporaneously Prepared Oral Liquid Page 2

Download in electronic PDF format for $75

Abstract:  Memantine, a N-methyl-D-aspartate receptor antagonist, was recently approved by the United States Food and Drug Administration for the palliative treatment of moderate to severe Alzheimer’s disease. Its suggested mechanism of action in the treatment of Alzheimer’s disease is binding to N-methyl-D-aspartate receptors, which results in inhibition of glutamate activity. Glutamate has been reported to contribute to the pathogenesis of Alzheimer’s disease by overstimulating the N-methyl-D-aspartate receptors, resulting in brain cell damage. The stability of memantine in an extemporaneously prepared oral liquid was studied. An aqueous liquid formulation was prepared by reconstituting memantine powder from triturated tablets with deionized water. The expected memantine concentration was 0.166 mg/mL. The memantine liquid was transferred into two glass prescription bottles; one was stored at room temperature (25°C), and the other in the refrigerator (2°C). Aliquots from each bottle were analyzed in quadruplicate on days 0, 1, 2, 3, 4, 7, 14, and 28 by using a gas chromatograph-mass spectrometer. The results of this study indicate that the extemporaneously prepared memantine oral liquid was stable for up to 7 days at room temperature and up to 28 days in the refrigerator.

Related Keywords: Weeranuj Yamreudeewong, PharmD, M. Glaucia Teixeira, PhD, Gabriele E. Mayer, PhD, memantine, N methyl D aspartate receptor antagonist, NMDA blocker, Alzheimer's disease, dementia, liquid formulation, stability

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Memantine in an Extemporaneously Prepared Oral Liquid
Yamreudeewong Weeranuj
, Teixeira M Glaucia, Mayer Gabriele E
Jul/Aug 2006
Pg. 316-317

Compounding and Characterization of Oral Disintegrating Films Containing Memantine Hydrochloride for Geriatrics
Rofiq Hanifah Mohd
, Phang Hiu Ching, Janakiraman Ashok Kumar, Chew Yik-Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin
Nov/Dec 2023
Pg. 512-521

Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations
Yamreudeewong Weeranuj
, Dolence Eric Kurt, Teixeira M Glaucia
Sep/Oct 2011
Pg. 435-437

Book Review: The NMDA Receptor
Jones Marty
Jan/Feb 2000
Pg. 26-27

Memantine Hydrochloride Capsules
Allen Loyd V Jr
Nov/Dec 2015
Pg. 511

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
Sep/Oct 2005
Pg. 339-346

Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet
Hazdi Siti Nursaqifah
, Phang Hiu Ching, Ng Zhi Qi, Chew Yik Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin
Nov/Dec 2023
Pg. 522-527

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 100-109

Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica
, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
Nov/Dec 2019
Pg. 504-510

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio
, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
May/Jun 2023
Pg. 250-255

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George
, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Jan/Feb 2018
Pg. 86-94

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets
Gupta Vishnu D
Nov/Dec 2001
Pg. 480-481

Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder
Gupta Vishnu D
Sep/Oct 2003
Pg. 386-388

Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Sep/Oct 2021
Pg. 431-439

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Return to Top